Capstan Medical

Capstan Medical is a private, pre-revenue medical device startup founded in 2021 and based in Santa Clara, California, with an R&D office in Santa Cruz. The company is developing an integrated platform that combines robotics, catheter technology, and novel implants to enable minimally invasive replacement of mitral and tricuspid heart valves, areas with no currently FDA-approved transcatheter replacement options. Led by a seasoned team with deep experience in cardiac devices and surgical robotics, Capstan aims to transform the standard of care for structural heart disease by reducing procedural invasiveness, improving precision, and shortening patient recovery times.

Integrated platform merging surgical robotics, catheter-based delivery systems, and next-generation heart valve implants for minimally invasive valve replacement procedures.

Capstan operates in the highly competitive and emerging transcatheter mitral/tricuspid therapy space, competing against large players like Edwards Lifesciences, Medtronic, and Abbott, as well as numerous startups (e.g., Cardiovalve, Venus Medtech, Cephea). Differentiation is sought through a unique robotic-assisted delivery platform aimed at improving precision over pure catheter-based systems.